{
    "nct_id": "NCT06322342",
    "official_title": "A Multi-Center, Phase 2, Open Label, Ascending Dose Study to Evaluate the Safety and Efficacy of RVP-001 and to Identify an Appropriate Dose to Detect CNS Lesions in Adult Patients",
    "inclusion_criteria": "1. Adults of all sexes, aged 18-75 years\n2. Patients with known enhancing CNS lesions, including but not limited to gliomas, meningiomas, glioblastomas, schwannomas, brain metastases, multiple sclerosis lesions, that are on an ongoing follow-up MRI schedule\n3. Patients who have had a GBCA-enhanced MRI within the past 14 days which demonstrated focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors, focal inflammatory disorders) including at least one enhancing lesion of minimum 5 mm (long axis)\n4. Acceptable renal function\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "1. Serious non-malignant disease that could compromise protocol objectives in the opinion of the investigator and/or the Sponsor\n2. Body mass index (BMI) greater than 35\n3. Patients with clinically significant cardiac disease\n4. MRI incompatibility",
    "miscellaneous_criteria": ""
}